Commonly used local anesthesia injections that cost less than Rs 100 could revolutionize breast treatment cancer, If used as an anticancer agent just before breast cancer surgery, 0.5 percent lidocaine can reduce the risk of death and recurrence by 29 percent and 30 percent, respectively. This is the finding of a decade-old, multi-centered study conducted by researchers at the Tata Memorial Center. Mumbai,
Surgery is an important intervention that offers a chance to cure cancer patients. But it often induces the formation of new metastatic disease – when it spreads from its original location to another part of the body. Now this local anesthesia stops the cancer cells from transmitting. “In a simple form, the intervention puts the cells to sleep, limiting their movement and potential for metastasis,” said Dr Rajendra Badve, principal investigator and director, Tata Memorial Center.
This is the first study of its kind globally that has shown substantial benefit from a single intervention before surgery.
what the research shows
Dr. Budway’s previous research has suggested that immediately before, during and immediately after surgical removal of a primary cancer there is a window of opportunity when anticancer interventions can reduce the risk of developing disseminated stage 4 metastatic cancer in a later lifetime. . Patient.
Dr. Budway explains how local anesthesia is injected a few minutes before the surgery. Then the surgeons wait about six minutes. Until then, the anesthesia renders the tumor less sensitive to events in its microenvironment. “In our initial study, we observed that the movement of cells during a surgical procedure is greater than before and after surgery. Therefore, once we let out the anesthesia, it allows us to control the movement.” and reduces the chances of recurrence and metastasis,” he said.
The study is a randomized controlled trial involving 1,600 women with operable breast cancer, half of whom received an injection of a commonly used drug around a tumor on the operating table just before surgery. All the women were diagnosed with early-stage breast cancer, which Dr Budway presented at the European Society of Medical Oncology (ESMO) Congress in Paris last week.
Dr Sudip Gupta, Professor of Medical Oncology at TMC and one of the co-investigators of the study, said, “This study provides an inexpensive and quickly implementable treatment in breast cancer that should be practiced by every surgeon treating the disease. The results of a large randomized trial, the gold standard way of evaluating the value of new treatments, provide the highest level of evidence to support the use of this technology. Indian centers can design and conduct studies with global impact.”
According to the World Health Organization (WHO), the survival rate of breast cancer patients for at least five years after diagnosis is 66 percent in India.
India sees about 150,000 new breast cancer patients annually. Most of them are detected late. Researchers believe that incorporating the intervention into the treatment of all breast cancer patients could save millions of lives.
Administration of 0.5 percent lidocaine prior to surgery will now be a standard protocol for early-stage surgery for all breast cancer patients at their centers for treatment. Dr. Budway said, “The intervention has low toxicity and side effects. It will be made part of the national guidelines for the treatment of breast cancer patients.
Doctors also have plans to conduct similar studies in cannabis. “It will also be tried for other cancer treatments where surgery is part of the treatment course,” Dr. Budway said.